Article and Video CATEGORIES
To close out the year, we're going to do our last webinar as part of our ongoing partnership with LUNGevity Foundation on the topic of small cell lung cancer (SCLC). While SCLC was the source of much of the excitement in the field of lung cancer 15 years ago, the focus in the last few years has been overwhelmingly on non-small cell lung cancer, and our programs and posts have reflected that. But SCLC still accounts for about 12-15% of lung cancer and over 20,000 cases in the US alone. It's a big enough area in the field of lung cancer that it's fitting that it be covered properly in our series of presentations on the field of lung cancer.
To do that, our upcoming webinar will feature Dr. Antoinette (Toni) Wozniak, medical oncologist and Professor of Medicine at Karmanos Cancer Center at Wayne State University in Detroit, MI. She will cover the background of the initial presentation, evaluation, and then the key elements of our current understanding of the best treatment for lung cancer. Finally, she'll discuss some ongoing questions and potential new treatments in this setting.
The program will be on Tuesday, December 18th, at 7 PM Eastern/4 PM Pacific. Following her live presentation of about 40-45 minutes, we'll finish out the hour with a question and answer session from our live audience. As always, the program is free, with registration through this link. Though we definitely hope to see you there, we'll have the program edited into podcasts that will be available here, on the LUNGevity Foundation website, and through iTunes and YouTube (you might even want to subscribe!).
I'll also note that in January we'll have our "Lung Cancer Highlights of 2012" program by Dr. Natasha Leighl from Princess Margaret Hospital in Toronto. We'll be posting details about that one soon.
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…